Journal of Gastrointestinal Infections

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  11 (2021)
Volume  10 (2020)
Volume  9 (2019)
Volume  8 (2018)
Volume  7 (2017)
Volume  6 (2016)
Volume  5 (2015)
Volume  4 (2014)
Volume  3 (2013)
Volume  2 (2012)
Related articles

VOLUME 9 , ISSUE 1 ( January-December, 2019 ) > List of Articles

Original Article

Association between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease

Supriya Mahajan, Juhi Khurana, Archana Rastogi, Ekta Gupta

Keywords : ELISA, Helicobacter pylori, IgA, IgG, IgM, NAFLD, NAS, NASH

Citation Information : Mahajan S, Khurana J, Rastogi A, Gupta E. Association between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease. J Gastrointest Infect 2019; 9 (1):5-9.

DOI: 10.5005/jp-journals-10068-3025

License: CC BY-NC 4.0

Published Online: 16-07-2020

Copyright Statement:  Copyright © 2019; The Author(s).


Abstract

Background: The role of Helicobacter pylori in extragastrointestinal diseases, though not clearly established, is of great importance. Objectives: The study aims to evaluate the role of H. pylori infection in nonalcoholic fatty liver disease (NAFLD) and its association with NAFLD severity. Materials and methods: Thirty-six patients with biopsy-proven NAFLD (17 patients with simple nonalcoholic fatty liver and 19 patients with nonalcoholic steatohepatitis—NASH) and 23 healthy blood donors (control group) were included in the study. Serum samples were tested for H. pylori antibodies IgG, IgM, and IgA using enzyme-linked immunosorbent assay (ELISA). Parameters associated with metabolic syndrome were compared between H. pylori seropositive and seronegative patients in the NAFLD group. Seroprevalence and antibody titers of H. pylori in the NAFLD group were compared with the control group. Results: Anti-H. pylori IgG was positive in 22 (61%) cases of the NAFLD group and 13 (56%) cases of the control group. Anti-H. pylori IgM was positive in 4 (11%) cases of the NAFLD group and 2 (8%) cases of the control group. Anti-H. pylori IgA seroprevalence in the NAFLD group (n = 11; 31%) was higher than the control group (n = 4; 17%; p = 0.03). The NAFLD group had a higher anti-H. pylori IgA titer than the control group (p = 0.03). There were similar rates of anti-H. pylori IgG/IgM/IgA titers between NAFLD and NASH patients with no significant correlation between H. pylori infection and metabolic syndrome. Conclusion: An association of H. pylori infection was seen in NAFLD cases which might have a role in the pathogenesis of fatty liver diseases. This can be further explored for its exact role in the causation of fatty liver disease.

HTML PDF Share
  1. Brunt EM, Janney CG, et al. Nonalcoholicsteatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94(9):2467–2474. DOI: 10.1111/j.1572-0241.1999.01377.x.
  2. Tiniakos DG, Vos MB, et al. Nonalcoholic fatty liver 2010;5:145–171. DOI: 10.1146/annurevpathol-121808-102132.
  3. Kleiner DE, Brunt EM, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41(6):1313–1321. DOI: 10.1002/hep.20701.
  4. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005;129(1):375–378. DOI: 10.1053/j.gastro.2005.05.041.
  5. Yilmaz Y. NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression? Semin Liver Dis 2012;32(1):14–21. DOI: 10.1055/s-0032-1306422.
  6. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholicsteatohepatitis. Semin Liver Dis 2001;21(1):27–41. DOI: 10.1055/s-2001-12927.
  7. Kalra S, Vithalani M, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT). J Assoc Physicians India 2013;61(7):448–453.
  8. Stalke P, Al-Soud WA, et al. Detection of Helicobacter species in liver and stomach tissues of patients with chronic liver diseases using polymerase chain reaction-denaturing gradient gel electrophoresis and im-munohistochemistry. Scand J Gastroenterol 2005;40(9):1032–1041. DOI: 10.1080/00365520510023251.
  9. Pirouz T, Zounubi L, et al. Detection of Helicobacter pylori in paraffin-embedded specimens from patients with chronic liver diseases, using the amplification method. Dig Dis Sci 2009;54(7):1456–1459. DOI: 10.1007/s10620-008-0522-5.
  10. Cindoruk M, Cirak MY, et al. Identification of Helicobacter species by 16S rDNA PCR and sequence analysis in human liver samples from patients with variousetiologies of benign liver diseases. Eur J Gastroenterol Hepatol 2008;20(1):33–36. DOI: 10.1097/MEG.0b013e3282efa4f2.
  11. Huang Y, Fan XG, et al. Identification of helicobacter species in human liver samples from patients with primary hepatocellular carcinoma. J Clin Pathol 2004;57(12):1273–1277. DOI: 10.1136/jcp.2004.018556.
  12. Taylor NS, Fox JG, et al. In vitro hepatotoxic factor in Helicobacter hepaticus, H. pylori and other Helicobacter species. J Med Microbiol 1995;42:48–52. DOI: 10.1099/00222615-42-1-48.
  13. Fukuda Y, Bamba H, et al. Helicobacter pylori infection increases mucosal permeability of the stomach and intestine. Digestion 2001;63(Suppl 1):93–96. DOI: 10.1159/000051918.
  14. Li M, Shen Z, et al. Potential role of Helicobacter pylori infection in non-alcoholic fatty liver disease. World J Gastroenterol 2013;19(41):7024–7031. DOI: 10.3748/wjg.v19.i41.7024.
  15. Dunn BE, Cohen H, et al. Helicobacter pylori. ClinMicrobiol Rev 1997;10(4):720–741. DOI: 10.1128/CMR.10.4.720.
  16. Kusters JG, van Vliet AH, et al. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19(3):449–490. DOI: 10.1128/CMR.00054-05.
  17. Banatvala N, Mayo K, et al. The cohort effect and Helicobacter pylori. J Infect Dis 1993;168(1):219–221. DOI: 10.1093/infdis/168.1.219.
  18. Polyzos SA, Kountouras J, et al. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter 2011;16(2):79–88. DOI: 10.1111/j.1523-5378.2011.00822.x.
  19. Figura N, Franceschi F, et al. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2010;15(Suppl 1):60–68. DOI: 10.1111/j.1523-5378.2010.00778.x.
  20. Suzuki H, Franceschi F, et al. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2011;16:65–69. DOI: 10.1111/j.1523-5378.2011.00883.x.
  21. Crabtree JE, Mahony MJ, et al. Immune responses to Helicobacter pylori in children with recurrent abdominal pain. J Clin Pathol 1991;44(9):768–771.
  22. Alem M, Alem N, et al. Diagnostic value of detection of IgM antibodies to Helicobacter pylori. Exp Mol Pathol 2002;72(1):77–83. DOI: 10.1006/exmp.2001.2408.
  23. Serrano CA, Gonzaez CG, et al. Lack of diagnostic utility of specific immunoglobulin M in Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2008;47(5):612–617. DOI: 10.1097/MPG.0b013e3181668648.
  24. Cherian S, Burgner DP, et al. Diagnosis of Helicobacter pylori infection in a highprevalencepediatric population: a comparison of 2 fecal antigen testing methods and serology. J Pediatr Gastroenterol Nutr 2008;47(2):130–135. DOI: 10.1097/MPG.0b013e31815bc5b3.
  25. Urita Y, Hike K, et al. Comparison of serum IgA and IgG antibodies for detecting Helicobacter pylori infection. Intern Med 2004;43(7):548–552. DOI: 10.2169/internalmedicine.43.548.
  26. Kosunen TU, Seppälä K, et al. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet 1992;339(8798):893–895. DOI: 10.1016/0140-6736(92)90929-W.
  27. Shirin H, Bruck R, et al. Evaluation of a new immunochromatographic test for Helicobacter pylori IgG antibodies in elderly symptomatic patients. J Gastroenterol 1999;34(1):7–10. DOI: 10.1007/s005350050209.
  28. Granberg C, Mansikka A, et al. Diagnosis of Helicobacter pylori infection by using pyloriset EIA-G and EIA-A for detection of serum immunoglobulin G (IgG) and IgA antibodies. J Clin Microbiol 1993;31(6):1450–1453.
  29. Polyzos SA, Kountouras J, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 2013;62(1):121–126. DOI: 10.1016/j.metabol.2012.06.007.
  30. Sumida Y, Kanemasa K, et al. Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease. J Gastroenterol 2015;50(9):996–1004. DOI: 10.1007/s00535-015-1039-2.
  31. Okushin K, Takahashi Y, et al. Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. BMC Gastroenterology 2015;15:25. DOI: 10.1186/s12876-015-0247-9.
  32. Baeg MK, Yoon SK, et al. Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease. World J Gastroenterol 2016;22(8):2592–2600. DOI: 10.3748/wjg.v22.i8.2592.
  33. Cai O, Huang Z, et al. Association between Helicobacter pylori infection and Nonalcoholic fatty liver disease: a single-center clinical study. Gastroenterology Research and Practice 2018;2018:8040262. DOI: 10.1155/2018/8040262.
  34. Kate V, Ananthakrishnan N, et al. Anti-H. pylori IgG seroprevalence rates in asymptomatic children and adults from South India. Indian J Med Microbiol 2001;19(2):20–25.
  35. Alaganantham TP, Pai M, et al. Seroepidemiology of Helicobacter pylori infection in an urban, upper class population in Chennai. Indian J Gastroenterol 1999;18:66–68.
  36. Graham DY, Adam E, et al. Seroepidemiologyof Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci 1991;36:1084–1088. DOI: 10.1007/BF01297451.
  37. Bhatia SJ, Abraham P. Helicobacter pylori in the Indian environment. Indian J Gastroenterol 1995;14:139–144.
  38. Gill HH, Desai HG, et al. Epidemiology of Helicobacter pylori: the Indian scenario. Indian J Gastroenterol 1993;12(1):9–11.
  39. Gill HH, Majumdar P, et al. Age related prevalence of Helicobacter pylori antibodies in Indian subjects. Indian J Gastroenterol 1994;13:92–94.
  40. Akbas HS, Basyigit S, et al. The assessment of carotid intima media thickness and serum paraoxonase-1 activity in Helicobacter pylori positive subjects. Lipids in Health and Dis 2010;9:92. DOI: 10.1186/1476-511X-9-92.
  41. Kebapcilar L, Bilgir O, et al. The effect of Helicobacter pylori eradication on macrophage migration inhibitory factor, C-reactive protein and fetuin a levels. Clinics (Sao Paulo) 2010;65(8):799–802. DOI: 10.1590/S1807-59322010000800010.
  42. Fan N, Peng L, et al. Helicobacter pylori infection is not associated with Non-alcoholic Fatty Liver Disease: A cross-sectional study in China. Front Microbiol 2018;9:73. DOI: 10.3389/fmicb.2018.00073.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.